Effects of intravenous lidocaine, dexmedetomidine, and their combination on IL-1, IL-6 and TNF-α in patients undergoing laparoscopic hysterectomy: a prospective, randomized controlled trial

Siqi Xu 1, Shenghong Hu 1, Xia Ju 1, Yuanhai Li 2, Qing Li 3 and Shengbin Wang 1*

Abstract

Background: Surgical-related inflammatory responses have negative effects on postoperative recovery. Intravenous (IV) lidocaine and dexmedetomidine inhibits the inflammatory response. We investigated whether the co-administration of lidocaine and dexmedetomidine could further alleviate inflammatory responses compared with lidocaine or dexmedetomidine alone during laparoscopic hysterectomy.

Methods: A total of 160 patients were randomly allocated into four groups following laparoscopic hysterectomy: the control group (group C) received normal saline, the lidocaine group (group L) received lidocaine (bolus infusion of 1.5 mg/kg over 10 min, 1.5 mg/kg/h continuous infusion), the dexmedetomidine group (group D) received dexmedetomidine (bolus infusion of 0.5 μg/kg over 10 min, 0.4 μg/kg/h continuous infusion), and the lidocaine plus dexmedetomidine group (group LD) received a combination of lidocaine (bolus infusion of 1.5 mg/kg over 10 min, 1.5 mg/kg/h continuous infusion) and dexmedetomidine (bolus infusion of 0.5 μg/kg over 10 min, 0.4 μg/kg/h continuous infusion). The levels of plasma interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) at different time points were the primary outcomes. Secondary outcomes included hemodynamic variables, postoperative visual analogue scale (VAS) scores, time to first flatus, and incidence of nausea and vomiting after surgery.

Results: The levels of plasma IL-1, IL-6, and TNF-α were lower in groups D and LD than in group C and were lowest in group LD at the end of the procedure and 2 h after the operation (P < 0.05). The VAS scores were decreased in groups D and LD compared with group C (P < 0.05). The heart rate (HR) was decreased at the end of the procedure and 2 h after the operation in groups D and LD compared to groups C and L (P < 0.001). The mean blood pressure (MBP) was lower at 2 h after the operation in groups L, D, and LD than in group C (P < 0.001). There was a lower incidence of postoperative nausea and vomiting (PONV) in group LD than in group C (P < 0.05).

(Continued on next page)
Background

Laparoscopic procedures are widely adopted for gynecological patients due to certain benefits, including decreased intensity of pain after surgery, improved postoperative recovery of intestinal function, and improved cosmetic effects [1]. However, tissue injury induced by surgical trauma stimulates the systemic inflammatory cascade to elicit the release of a large number of inflammatory cytokines [2]. High levels of inflammatory cytokines not only affect wound healing but may also be associated with a large number of complications, such as postoperative pain, fatigue, and cognitive dysfunction [3–5]. Dexmedetomidine, a highly selective alpha 2-adrenergic agonist, can lead to hypnosis, sedation, analgesia and minimal respiratory depression [6]. As an anesthetic adjuvant, in view of reducing catecholamine release [7], sparing opioids [8], and improving the quality of recovery during the anesthesia period [9, 10], dexmedetomidine has been widely used in the clinical setting. Animal and clinical studies have revealed that the systemic administration of dexmedetomidine may exert anti-inflammatory effects [11, 12]. The systemic administration of lidocaine has been increasingly used for surgical patients due to its potential beneficial effects, including opioid-sparing [13], analgesic [14] and anti-inflammatory properties [15]. Our previous study indicated that dexmedetomidine plus lidocaine infusion may further decrease the intensity of postoperative pain, lower the requirement of fentanyl after surgery, and accelerate bowel function recovery than lidocaine or dexmedetomidine infusion alone [16]. Although intravenous lidocaine and dexmedetomidine infusion alone may exert anti-inflammatory efficacy, the degree to which the combination of lidocaine and dexmedetomidine infusion inhibits the inflammatory response has not been evaluated. Therefore, we hypothesized that the co-administration of lidocaine and dexmedetomidine could further decrease the levels of plasma TNF-α, IL-6, and IL-1 compared with lidocaine and dexmedetomidine alone after laparoscopic hysterectomy.

Methods

The research approach was approved by the Ethics Committee of Anqing Municipal Hospital and registered at www.clinicaltrials.gov (Number: NCT03276533, registration date: 08/23/2017). All methods were performed in accordance with the relevant guidelines and regulations in our present study. All subjects provided informed consent at least 12 h before surgery. The inclusion criteria of our trial included American Society of Anesthesiologists (ASA) physical status I and II, age between 40 and 65 years, and undergoing laparoscopic hysterectomy with general anesthesia. The exclusion criteria included a history of allergy to local anesthetics, preoperative atrioventricular block and bradycardia, impaired kidney or liver function, underlying severe respiratory disease, and a history of opioid use and psychiatric disease. Patients were randomized into four groups (groups L, D, LD, and C) by a nurse in the postanesthesia care unit (PACU) who did not participate in the study according to computer-generated random numbers and sealed envelopes. Patients in group L received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h, which was ceased 30 min before the end of the operation [17]. Patients in group D received a bolus infusion of dexmedetomidine (0.5 μg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h, which was ceased 30 min before the end of operation [16]. Patients in group LD received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 μg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 μg/kg/h, respectively, which were ceased 30 min before the end of the operation. Patients in group C received the same volume of normal saline (40 mL) 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume (40 mL/h), and ceased 30 min before the end of the operation. Study participants, including anesthesiologists, clinicians, and subjects, were blinded to the treatment assignments. The drug solutions in each group were provided by a nurse in the PACU who did not participate in the trial.

The primary endpoints in our study included the levels of plasma IL-1, IL-6, and TNF-α at different time points. The secondary endpoints included intraoperative propofol and remifentanil consumption, HR, MBP, VAS scores, time to first flatus, incidence of nausea and vomiting after the operation, and rescue analgesics (fentanyl).
Basal vital signs, including MBP, peripheral oxygen saturation (SPO2), electrocardiogram (ECG), HR and pressure of end-tidal CO2 (PetCO2), were established for each patient. All subjects received Ringer’s lactate (4–6 mL/kg/h) for compensatory capacity after arriving at the operating room. To reserve sufficient oxygenation, before the induction of anesthesia, all patients were given continuously oxygen (100%) for 3 to 5 min via a facemask. The induction of general anesthesia in all four groups was implemented with a target-controlled infusion (TCI) of plasma remifentanil and propofol. The initial TCI level of plasma propofol was set as 3.0 μg/mL [18]. The initial TCI level of plasma remifentanil was set as 5.0 ng/mL [19] 3 min after propofol infusion, and then cis-atracurium (0.15 mg/kg) was administered intravenously. Mechanical ventilation was implemented with an anesthesia machine (Aespire View, Datex-Ohmeda, USA). Respiratory parameters were adjusted to set PetCO2 between 35 mmHg and 45 mmHg. To maintain muscle relaxation during the anesthesia period, a supplemental dose of cis-atracurium was injected intermittently. During the surgery, BIS values were maintained between 50 and 60 by adjusting the TCI concentrations of plasma propofol during the anesthesia period in all patients. The hemodynamic variables were maintained within 20% of the preoperative baseline values by adjusting the infusion plasma concentrations of propofol and remifentanil. When patients had MBP < 60 mmHg or HR < 50 beats/min, ephedrine (6 mg) or atropine (0.5 mg) was intravenously administered, respectively. Fentanyl (1 μg/kg) was given intravenously 30 min before the end of surgery to alleviate the intensity of pain after surgery, and patient-controlled intravenous analgesia (PCIA) with 0.3 μg/kg/h fentanyl (a total regimen of 100 ml) was connected to each patient to deliver a bolus of fentanyl (0.075 μg/kg) with a 15-min lockout interval. Propofol and remifentanil infusions were terminated at the end of the procedure, and ondansetron (0.1 mg/kg) was injected to prevent nausea and vomiting after the operation. Neostigmine (20 μg/kg) and atropine (10 μg/kg) were injected intravenously to reverse neuromuscular blockade when spontaneous respiration sufficiently recovered. The endotracheal tube was removed when the train-of-four (TOF) ratio was at least 0.9 and patients were able to open their eyes according to verbal instructions. The patients were transferred to the PACU by an anesthesiologist 5 min after the endotracheal tube was removed. All patients were observed for 2 h in the PACU. The surgical procedure was completed by the same operative team, and the target pressure of carbon dioxide (CO2) pneumoperitoneum was maintained between 10 mmHg and 12 mmHg during the perioperative period.

The levels of plasma IL-1, IL-6, and TNF-α were measured at different time points, including baseline, the end of surgery, and 2 and 24 h after the operation. Blood samples from each patient were placed in tubes and centrifuged within 30 min, and plasma was separated and stored at −70°C until analysis. Enzyme-linked immunosorbent assay kits (KANU BIOLOGICAL TECHNOLOGY CO., Ltd., Shanghai, China) were used to test the levels of cytokines.

A 10-cm visual analogue scale (VAS) was used to assess the intensity of pain after the operation during the first 24 h period (0 = no pain; 10 = most imaginable pain). A total of 25 μg of fentanyl was injected when the postoperative VAS score was > 3 and until the VAS score was ≤3.

The MBP and HR were recorded at baseline, at the end of surgery, and 2 h after the operation. Intraoperative propofol and remifentanil consumption, the operating time, the anesthesia time, VAS scores, the incidence of nausea and vomiting, rescue analgesics, and time to first flatus were recorded after surgery.

Sample size calculation

Based on our pilot study, we chose the levels of plasma IL-1, IL-6, and TNF-α as the primary outcome. This study was powered to detect a difference in the plasma levels of IL-1, IL-6, and TNF-α among the four arms with a β value set at 20% and α value set at 5% from PASS software. The mean and SD values of plasma IL-1, IL-6, and TNF-α at the end of surgery in all four groups were as follows: XCon = 2.6 pg/mL, XLido = 2.4 pg/mL, XDex = 2.3 pg/mL, XLido + Dex = 2.1 pg/mL, SCon = 0.5 pg/mL, SLido = 0.5 pg/mL, SDex = 0.3 pg/mL, XLido + Dex = 0.3 pg/mL; XCon = 22.2 pg/mL, XLido = 20.9 pg/mL, XDex = 19.0 pg/mL, XLido + Dex = 17.7 pg/mL, SCon = 5.9 pg/mL, SLido = 5.3 pg/mL, SDex = 4.8 pg/mL, SLido + Dex = 4.7 pg/mL; and XCon = 41.6 pg/mL, XLido = 39.9 pg/mL, XDex = 37.8 pg/mL, XLido + Dex = 32.9 pg/mL, SCon = 7.2 pg/mL, SLido = 8.4 pg/mL, SDex = 8.9 pg/mL, SLido + Dex = 7.9 pg/mL. Therefore, 32, 33, and 22 subjects for each group were respectively obtained, and considering a possible 20% dropout rate, we ultimately intended to recruit a total of 40 subjects for each arm.

Statistical analysis

We used SPSS v.17 (IBM Corp., Armonk, NY, USA) software to complete the statistical analyses in the present study. Data are expressed as the number or mean ± standard deviation. The χ² test or Fisher’s exact test, as appropriate, was used for categorical data analysis. One-way analysis of variance (ANOVA) was used for continuous data analysis in all four groups. Repeated measures design analysis of variance was applied to compare differences in plasma IL-1, IL-6, and TNF-α and MBP and HR at different time points in all four groups. If group differences were found by ANOVA to be significant, Tukey's post-hoc test was performed for
further analysis. Statistical significance was defined as a $P$ value < 0.05.

**Results**

A total of 176 subjects were recruited for our trial, and sixteen patients were excluded, (nine patients with a history of preoperative bradycardia and seven patients who did not agree to participate in the study). Eventually, 160 subjects completed the present study. Data obtained from forty subjects in each arm were analysed (Fig. 1).

No significant differences were observed in any of the four arms in regard to ASA physical status, age, BMI, duration of the operation, weight, or duration of anesthesia (Table 1).

**Intraoperative consumption of remifentanil and propofol**

The consumption of remifentanil and propofol was significantly decreased in groups L, D, and LD compared to group C ($P < 0.001$). The consumption of remifentanil and propofol was lowest in group LD during the intraoperative period ($P < 0.001$). There were no significant differences in the intraoperative consumption of propofol and remifentanil between groups L and D ($P = 0.740$ and $P = 0.097$) (Table 2).

**Postoperative VAS scores at rest**

The VAS scores in groups L, D, and LD were significantly decreased compared to those in group C at 2 and 6 h after the operation ($P = 0.022$, $P = 0.028$, $P < 0.001$, $P < 0.001$, and $P < 0.001$, respectively). The VAS scores in group LD were lower than those in the other three groups at 2, 6, and 12 h after surgery ($P < 0.01$). There were no significant differences in postoperative VAS scores between groups L and D ($P = 0.054$, $P = 0.168$, $P = 0.144$, $P = 0.839$, respectively) (Table 3).

**Time to first flatus**

The time to first flatus in groups L and LD was shorter than that in groups C and D ($P = 0.005$, $P = 0.012$, $P < 0.001$, and $P = 0.992$, respectively). There was no significant differences in the time to first flatus between groups C and D ($P = 0.992$) (Table 2).

**Incidence of nausea and vomiting after the operation**

The number of patients who experienced nausea and vomiting in group LD (25%) was less than that in group C (52.5%) during the first 24 h after the operation.
operation \((P = 0.012)\). There were no differences with respect to PONV in groups L (42.5%) and D (32.5%) compared to group C (52.5%) \((P = 0.370\) and \(P = 0.070)\). The incidence of PONV was lowest in group LD (Table 2).

### The levels of plasma TNF-\(\alpha\), IL-6, and IL-1 at different time points

The levels of plasma TNF-\(\alpha\), IL-6, and IL-1 were not significantly different between the four groups at baseline. Compared to baseline, the levels of plasma TNF-\(\alpha\), IL-6, and IL-1 were significantly elevated at the end of the operation and 2 h after surgery (all \(P < 0.001)\). Compared to group C, the levels of plasma TNF-\(\alpha\), IL-6, and IL-1 were significantly decreased at the end of the operation and 2 h after surgery in groups D and LD (all \(P < 0.05\)). The levels of plasma TNF-\(\alpha\), IL-6, and IL-1 were lower at the end of the operation and 2 h after surgery in group LD than in groups L and D (all \(P < 0.05\)). The levels of plasma TNF-\(\alpha\), IL-6, and IL-1 were not significantly different during the perioperative period or during the first 24 h after surgery between groups L and D. The levels of plasma TNF-\(\alpha\), IL-6, and IL-1 were not significantly different at 24 h after surgery in all four groups (Table 4).

### MBP and HR at different time points

The MBP was significantly decreased in groups L, D, and LD at 2 h after surgery compared with group C \((P = 0.034,\ P = 0.005,\ \text{and}\ P < 0.001,\ \text{respectively})\). Compared with group C, the MBP was significantly lower at 2 h after surgery in group LD \((P = 0.044)\). HR was significantly lower in groups D and LD at the end of surgery and 2 h after surgery than in groups C and L (all \(P < 0.001)\) (Table 5).

### Discussion

A significant finding from our trial was that the intraoperative combination of lidocaine and dexmedetomidine infusion further reduced inflammatory responses compared with lidocaine or dexmedetomidine infusion alone in patients following laparoscopic hysterectomy. Patients who received lidocaine plus dexmedetomidine infusion were associated with lower levels of plasma IL-1, IL-6, and TNF-\(\alpha\) at the end of the operation and 2 h after surgery, lower VAS scores after surgery, and less intraoperative consumption of remifentanil and propofol compared with patients who received lidocaine or dexmedetomidine infusion alone. The co-administration of lidocaine and dexmedetomidine also resulted in a lower incidence of PONV.

Surgical-related tissue damage induces stress responses in the body, and further promotes the release of perioperatively inflammatory cytokines, including IL-1, IL-6, and TNF-\(\alpha\) \([20]\). The harmful inflammatory responses caused by surgical procedures have negative effects on postoperative outcomes in surgical patients and increase morbidity and mortality. The suppression of perioperative inflammatory responses is associated with less postoperative pain and improves postoperative outcomes. Therefore, it is important to effectively alleviate perioperative inflammatory responses for patients following surgery, especially major surgery. Animal experiments

### Table 1 Characteristics of patients

| Variable               | Group C \((n = 40)\) | Group L \((n = 40)\) | Group D \((n = 40)\) | Group LD \((n = 40)\) | \(P\) value |
|------------------------|-----------------------|----------------------|----------------------|-----------------------|------------|
| Age (years)            | 47.2 ± 4.8            | 48.1 ± 5.6           | 47.8 ± 4.9           | 47.3 ± 5.4           | 0.848      |
| Weight (kg)            | 59.9 ± 6.7            | 59.2 ± 6.3           | 57.8 ± 6.7           | 58.9 ± 6.2           | 0.541      |
| BMI                    | 24.6 ± 2.6            | 24.3 ± 2.3           | 23.8 ± 2.4           | 24.0 ± 2.2           | 0.402      |
| Anesthesia time (min)  | 118.3 ± 9.2           | 120.7 ± 7.2          | 118.6 ± 7.7          | 120.2 ± 7.9          | 0.478      |
| Operation time (min)   | 99.6 ± 10.4           | 101.0 ± 11.1         | 98.9 ± 7.2           | 100.2 ± 7.9          | 0.827      |
| ASA physical status (I / II) | 21/19 | 18/22 | 23/17 | 20/20 | 0.729 |

Data are presented as mean ± standard deviation (SD)

*\(C\) control, \(L\) lidocaine, \(D\) dexmedetomidine, \(LD\) lidocaine and dexmedetomidine combination

\(\star P < 0.05\) versus group C, \(\star\star P < 0.05\) versus group L, \(\star\star\star P < 0.05\) versus group D

### Table 2 Doses of propofol, remifentanil, rescue anesthetic, first flatus time, and incidence of PONV

| Index                   | Group C \((n = 40)\) | Group L \((n = 40)\) | Group D \((n = 40)\) | Group LD \((n = 40)\) | \(P\) value |
|-------------------------|-----------------------|----------------------|----------------------|-----------------------|------------|
| Propofol dose (mg)      | 702.6 ± 56.3          | 650.3 ± 46.8         | 640.0 ± 39.0         | 554.0 ± 35.3          | < 0.001    |
| Remifentanil dose (microg) | 965.4 ± 87.7          | 835.8 ± 59.3         | 799.2 ± 68.9         | 500.6 ± 62.1          | < 0.001    |
| Rescue anesthetic (microg) | 33.8 ± 22.3           | 21.3 ± 19.2          | 0.0 ± 0.0            | 0.0 ± 0.0            | < 0.001    |
| First flatus time (hours) | 23.1 ± 3.8            | 20.4 ± 3.3           | 22.8 ± 3.4           | 19.9 ± 3.4           | < 0.001    |
| PONV (percentage)       | 21 (52.5)             | 17 (42.5)            | 13 (32.5)            | 10 (25)              | 0.036      |
### Table 3: VAS scores at rest during the first 24 h after operation

|                  | Group C (n = 40) | Group L (n = 40) | Group D (n = 40) | Group LD (n = 40) | P value |
|------------------|------------------|------------------|------------------|-------------------|---------|
| 2 h after surgery| 3.3 ± 0.7        | 2.9 ± 0.6        | 2.5 ± 0.6        | 1.8 ± 0.6         | <0.001  |
| 6 h after surgery| 3.4 ± 0.8        | 3.0 ± 0.8        | 2.6 ± 0.7        | 1.7 ± 0.6         | <0.001  |
| 12 h after surgery| 2.7 ± 0.6      | 2.5 ± 0.8        | 2.2 ± 0.8        | 1.6 ± 0.7         | <0.001  |
| 24 h after surgery| 2.0 ± 0.7      | 1.7 ± 0.7        | 1.5 ± 0.6        | 1.3 ± 0.6         | <0.001  |

Data are presented as mean ± standard deviation (SD)

C control, L lidocaine, D dexmedetomidine, LD lidocaine and dexmedetomidine combination

★ P < 0.05 versus group D

### Table 4: Comparison of plasma IL-1, IL-6, and TNF-α levels at different time points

| Cytokines | Groups | T0           | T1           | T2           | T3           | P value |
|-----------|--------|--------------|--------------|--------------|--------------|---------|
| IL-1 (pg/ml) |       |              |              |              |              |         |
| Group C   | 1.27 ± 0.35 | 2.72 ± 0.56  | 3.18 ± 0.57  | 1.53 ± 0.36  |             |         |
| Group L   | 1.36 ± 0.27 | 2.56 ± 0.52  | 2.97 ± 0.53  | 1.51 ± 0.31  |             |         |
| Group D   | 1.38 ± 0.33 | 2.41 ± 0.48  | 2.83 ± 0.59  | 1.55 ± 0.37  |             |         |
| Group LD  | 1.35 ± 0.36 | 2.02 ± 0.45  | 2.36 ± 0.47  | 1.56 ± 0.34  |             |         |
| aP        | 0.599 | 0.519        | 0.290        | 0.907        |             |         |
| bP        | 0.431 | 0.035        | 0.030        | 0.396        |             |         |
| cP        | 0.744 | <0.001       | <0.001       | 0.221        |             |         |
| dP        | 0.993 | 0.519        | 0.656        | 0.805        |             |         |
| eP        | 0.995 | <0.001       | <0.001       | 0.594        |             |         |
| fP        | 0.958 | 0.04         | 0.001        | 0.985        |             |         |
| IL-6 (pg/ml) |       |              |              |              |              |         |
| Group C   | 11.33 ± 2.57 | 23.98 ± 6.37 | 26.05 ± 7.26 | 12.65 ± 3.18 |             |         |
| Group L   | 10.95 ± 2.46 | 23.03 ± 5.87 | 23.18 ± 5.07 | 12.00 ± 3.11 |             |         |
| Group D   | 10.40 ± 2.94 | 20.60 ± 5.03 | 21.75 ± 4.91 | 11.43 ± 3.34 |             |         |
| Group LD  | 10.65 ± 2.66 | 17.15 ± 4.82 | 18.30 ± 5.31 | 11.18 ± 3.11 |             |         |
| aP        | 0.992 | 0.870        | 0.115        | 0.798        |             |         |
| bP        | 0.408 | 0.037        | 0.005        | 0.317        |             |         |
| cP        | 0.669 | <0.001       | <0.001       | 0.168        |             |         |
| dP        | 0.792 | 0.211        | 0.681        | 0.851        |             |         |
| eP        | 0.958 | <0.001       | <0.001       | 0.654        |             |         |
| fP        | 0.975 | 0.031        | 0.038        | 0.985        |             |         |
| TNF-α (pg/ml) |      |              |              |              |              |         |
| Group C   | 12.55 ± 2.21 | 44.28 ± 6.89  | 76.10 ± 10.65 | 14.78 ± 3.49  |             |         |
| Group L   | 12.80 ± 2.28 | 41.18 ± 8.55  | 73.13 ± 9.31  | 14.30 ± 2.66  |             |         |
| Group D   | 12.93 ± 2.35 | 38.80 ± 9.84  | 69.45 ± 8.75  | 13.80 ± 2.96  |             |         |
| Group LD  | 13.13 ± 2.64 | 33.78 ± 6.92  | 62.95 ± 11.33 | 13.43 ± 3.53  |             |         |
| aP        | 0.965 | 0.326        | 0.590        | 0.909        |             |         |
| bP        | 0.894 | 0.016        | 0.019        | 0.520        |             |         |
| cP        | 0.700 | <0.001       | <0.001       | 0.233        |             |         |
| dP        | 0.995 | 0.562        | 0.363        | 0.896        |             |         |
| eP        | 0.928 | <0.001       | <0.001       | 0.609        |             |         |
| fP        | 0.982 | 0.032        | 0.023        | 0.952        |             |         |

Data are presented as mean ± standard deviation (SD)

T0 baseline, T1 at the end of surgery, T2 2 h after surgery, T3 24 h after surgery, C control, L lidocaine, D dexmedetomidine, LD lidocaine and dexmedetomidine combination

★ P < 0.05 compared with T0, aP for group C versus group L, bP for group C versus group D, cP for group C versus group LD, dP for group L versus group D, eP for group L versus group LD, fP for group D versus group LD
suggest that dexmedetomidine administration exerts some degree of protection for organs such as the lung [21], kidney [22], and brain [23]. The effects are associated with the anti-inflammatory property of dexmedetomidine. Kang et al. [24] found that dexmedetomidine reduced the levels of IL-1β and TNF-α at the end of peritoneal closure and 1 h after the operation in patients undergoing laparoscopic cholecystectomy. Dong et al. [25] revealed that systemic dexmedetomidine infusion decreased the levels of IL-1β, IL-6, TNF-α, and C-reactive protein (CRP) at 1 h before the end of surgery and 24 h after surgery. The results of the present study indicated that dexmedetomidine infusion resulted in lower plasma IL-1β, IL-6, and TNF-α concentrations at the end of the operation and 2 h after surgery as well as lower VAS scores at 2, 6, 12 and 24 h after surgery compared with normal saline infusion. Furthermore, the infusion of lidocaine combined with dexmedetomidine significantly decreased the levels of plasma IL-1β, IL-6, and TNF-α at the end of the operation and 2 h after surgery and alleviated pain at 2, 6, and 12 h compared to the infusion of dexmedetomidine alone. This suggests that lidocaine plus dexmedetomidine infusion further suppresses the secretion of inflammatory cytokines and improves the postoperative intensity of pain compared with dexmedetomidine infusion alone and that postoperative pain relief may be associated with lower levels of plasma IL-1β, IL-6, and TNF-α. Anti-inflammatory and analgesic effects of combination regimen decrease postoperative pain intensity and requirement of opioids, which reduce adverse effects associated with opioids, including PONV, delayed recovery of intestinal function, etc. Furthermore, it may be decrease cost and time of hospital and improve patient satisfaction in the clinical practice.

Lidocaine, an amide local anesthetic, is used for local anesthesia and to treat ventricular arrhythmias in the clinical setting. Currently, clinical studies have shown that intravenous lidocaine administration decreases opioid consumption [26] and postoperative pain [27] and accelerates bowel function recovery [28]. Sridhar et al. [29] showed that intravenous lidocaine was associated with low levels of CRP and IL-6 during the post-operative period following selective open abdominal surgeries. Song et al. [30] revealed that intravenous lidocaine infusion attenuated the initiation of an excessive inflammatory response during laparoscopic surgery and was associated with low levels of serum IL-6 and IL-8. Our results demonstrated that intravenous lidocaine did not significantly decrease the levels of plasma IL-1, IL-6, and TNF-α compared to intravenous normal saline. The cause of the inconsistent results may be associated with the dosage of lidocaine, type of surgery, and duration of continuous lidocaine infusion. The levels of plasma IL-1, IL-6, and TNF-α in group LD were lower than those in groups L and D. This suggested that the combination of lidocaine and dexmedetomidine infusion further alleviated inflammatory responses resulting from surgical trauma compared with lidocaine or dexmedetomidine infusion alone. This effect is attributed to following factors. (1) Lidocaine combined with dexmedetomidine may further attenuate the surgical stress response. (2) Lidocaine and dexmedetomidine may exert anti-inflammatory properties by different mechanisms of action. (3) The combination of lidocaine and dexmedetomidine infusion may exert additive anti-inflammatory effects. Our results also showed that lidocaine infusion was associated with lower VAS scores at 2 and 6 h after surgery, and a shorter time to first flatus. This finding suggests that lidocaine infusion may decrease early postoperative pain and facilitate faster bowel function in patients undergoing laparoscopic hysterectomy.

As an adjuvant drug, dexmedetomidine has been related to attenuating the MBP and HR and the response to surgical procedures. Several studies have demonstrated that the most common side effect of dexmedetomidine administration is bradycardia, which may or may not be accompanied by a transient increase in MAP [31–33]. Hence, we selected a smaller dose (0.5 μg/kg loading, 0.4 μg/kg/h infusion) in the present study to decrease adverse effects, including bradycardia, hypertension, and hypotension, and to avoid delayed recovery after the operation. Hemodynamic variables were stable at 2 h after surgery in groups D and LD. HR significantly decreased in groups D and LD compared to group C at the end of the operation and 2 h after surgery. Although lidocaine plus dexmedetomidine infusion and dexmedetomidine infusion alone increased the incidence of bradycardia in the present study, we found that HR <

| Variables | Groups | T0 | T1 | T2 |
|-----------|--------|----|----|----|
| MAP (mmHg) | Group C | 79.2 ± 8.2 | 73.9 ± 4.3 | 77.1 ± 5.1 |
| Group L | 78.6 ± 8.5 | 73.3 ± 5.1 | 74.2 ± 4.7^** |
| Group D | 81.4 ± 7.1 | 72.2 ± 5.9 | 73.6 ± 4.4^** |
| Group LD | 80.1 ± 6.2 | 71.1 ± 4.5^** | 71.5 ± 4.6^** |
| HR (bpm) | Group C | 74.3 ± 9.0 | 66.9 ± 6.3^** | 71.8 ± 5.7 |
| Group L | 72.6 ± 8.5 | 66.3 ± 6.6^** | 68.6 ± 7.7 |
| Group D | 74.8 ± 9.1 | 60.4 ± 5.2^** | 60.9 ± 5.4^** |
| Group LD | 73.8 ± 9.2 | 60.0 ± 5.0^** | 60.2 ± 4.8^** |

Data are presented as mean ± standard deviation (SD)

© 2021 Xu et al. BMC Anesthesiology
50 bpm rarely occurred during the intraoperative period or during the PACU stay period after surgery. PONV is prevalent in patients following gynecological laparoscopic surgery. The present study showed that patients who received lidocaine plus dexmedetomidine had a lower incidence of PONV than those receiving normal saline. The possible reasons include lower postoperative pain intensity and inflammatory cytokines.

Our study had several limitations. On the one hand, we only recorded a few inflammatory cytokines, including IL-1, IL-6, and TNF-α, and did not perform clinical measurements associated with inflammatory responses. On the other hand, we only observed the levels of plasma IL-1, IL-6, and TNF-α at the end of surgery and 2 and 24 h after surgery. These time points may not effectively reflect the levels of plasma IL-1, IL-6, and TNF-α caused by surgical insult in a time-dependent manner. Finally, we only focused on the intraoperative effects of lidocaine combined with dexmedetomidine following laparoscopic hysterectomy. This was a short study and lacked recovery profile assessments, such as patient satisfaction.

Conclusions
The intraoperative combination of lidocaine and dexmedetomidine infusion further alleviated inflammatory responses, decreased postoperative pain, and led to fewer PONV in patients undergoing laparoscopic hysterectomy than either drug alone. Moreover, the improvement in postoperative pain and PONV may be associated with the suppression of inflammatory cytokines.

The future perspectives
The development of ERAS and minimization of opioid or free opioid use may improve the recovery quality of patients. The inflammatory response may be associated with perioperative neurocognitive disorders (PNDs). The co-administration of lidocaine and dexmedetomidine may provide better anti-inflammatory and analgesic effects than lidocaine or dexmedetomidine alone. Therefore, the effects of the combination regimen on PNDs and the feasibility of the method for minimizing opioid or free opioid use were the points of concern.

Abbreviations
IV: Intravenous; ASA: American Society of Anesthesiologists; IL-1: Interleukin-1; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α; MBP: Mean blood pressure; HR: Heart rate; CO2: Carbon dioxide; PONV: Postoperative nausea and vomiting; PACU: Postanesthesia care unit; SPO2: Peripheral pulse oximeter; ECG: Electrocardiogram; PetCO2: Pressure of end-tidal CO2; TCI: Target-controlled infusion; PCIA: Patient-controlled intravenous analgesia; TOF: Train of four; VAS: Visual analogue scale; SD: Standard deviation; ANOVA: One-way analysis of variance; CRP: C-reactive protein; MAP: Mean arterial pressure

Acknowledgements
Not applicable.

Authors’ contributions
SQX contributed to study design, data collection, statistical analysis, drafting the manuscript, and revised the manuscript. SHH contributed to data collection and revised the manuscript. XJ contributed to data collection and study design. YHL was engaged in the design of the study and helped to the revision of the manuscript. QL participated in the design of the study and was responsible for clinical coordination. SBW designed the study, revised the manuscript, and interpreted the data. All authors read and approved the final manuscript.

Funding
This study was supported by Clinical Research Fund of Anhui Medical University (2019kjx224).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Anqing Municipal Hospital on 10, August, 2017. Written informed consent was obtained from each participant.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Anesthesiology, The Affiliated Anqing Hospital of Anhui Medical University, Anqing 246000, China. 2Department of Anesthesiology of Anhui Medical University, Anqing 246000, China. 3Department of Gynaecology and Obstetrics, The Affiliated Anqing Hospital of Anhui Medical University, Anqing 246000, China.

Received: 10 September 2020 Accepted: 14 December 2020
Published online: 06 January 2021

References
1. Aarts JW, Nieboer TE, Johnson N, Tavender E, Lavender E, Garry R, Mol BW, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2015;8:CD003677.
2. Li Y, Wang B, Zhang L, He SF, Hu XW, Wong GT, et al. Dexmedetomidine combined with general anesthesia provides similar intraoperative stress response reduction when compared with a combined general and epidural anesthetic technique. Anesth Analg. 2016;123(4):1202–10.
3. Li YC, Xi CH, An YF, Dong WH, Zhou M. Intraoperative inflammatory response and protein S-100β concentrations-relationship with postoperative cognitive dysfunction in elderly patients. Acta Anaesthesiol Scand. 2012;56(5):595–600.
4. Hsing CH, Wang JJ. Clinical implication of perioperative inflammatory cytokine alteration. Acta Anaesthesiol Taiwanica. 2015;53(1):23–8.
5. Abdelmalak BB, You J, Kurz A, Kot M, Bralliar T, Remzi FH, et al. Effects of dexamethasone, light anesthesia, and tight glucose control on postoperative cognitive dysfunction in elderly patients. Acta Anaesthesiol Scand. 2019;55(5):593–601.
6. Kisik D, Malec E, Schmidt C. Use of dexmedetomidine in pediatric cardiac anesthesia. Curr Opin Anaesthesiol. 2019;32(2):1457–63.
7. Chen Y, Feng X, Hu X, Sha J, Li B, Zhang H, et al. Dexmedetomidine ameliorates acute stress-induced kidney injury by attenuating oxidative stress and apoptosis through inhibition of the ROS/JNK signaling pathway. Oxidative Med Cell Longev. 2018;2018:8035310.
8. Peng K, Zhang J, Meng XW, Liu HY, JF FH. Optimization of postoperative intravenous patient-controlled analgesia with opioid-dexmedetomidine combinations: an updated meta-analysis with trial sequential analysis of randomized controlled trials. Pain Physician. 2017;20(7):569–96.
9. Shin HW, Yoo HN, Kim DH, Lee H, Shin HH, Lee HW. Preanesthetic dexmedetomidine 1 μg/kg single infusion is a simple, easy, and economic adjuvant for general anesthesia. Korean J Anesthesiol. 2013;65(2):114–20.
10. Bekker A, Halle M, Klime R, Didehrav S, Babu R, Martiniuk F, et al. The effect of intraoperative infusion of dexmedetomidine on the quality of recovery after major spinal surgery. J Neurosurg Anesthesiol. 2013;25(1):16–24.

11. Liu M, Yi Y, Zhao M. Effect of dexmedetomidine anesthesia on perioperative levels of TNF-α and IL-6 in patients with ovarian cancer. Oncol Lett. 2019;17(6):5517–22.

12. Xue BB, Chen BH, Tang YN, Weng CW, Lin LN. Dexmedetomidine protects against lung injury induced by limb ischemia-reperfusion via the TLR4/MyD88/NF-κB pathway. Kaohsiung J Med Sci. 2019;35(11):1–7.

13. Omar E, Wallon G, Bauer C, Axiotis G, Bouik C, Soubriou JL, et al. Evaluation of intravenous lidocaine in head and neck cancer surgery: study protocol for a randomized controlled trial. Trials. 2019;20(1):220.

14. Wei S, Yu-Han Z, Wei-Wei J, Hai Y. The effects of intravenous lidocaine on wound pain and gastrointestinal function recovery after laparoscopic colorectal surgery. Int Wound J. 2020;17(2):1–12.

15. Ortiz MP, Godoy MC, Schlösser RS, Ortiz RP, Godoy JP, Santiago ES, et al. Effect of endovenous lidocaine on analgesia and serum cytokines: double-blinded and randomized trial. J Clin Anesth. 2016;35:70–7.

16. Xu SQ, Li YH, Wang SB, Hu SH, Ju X, Xiao JB. Effects of intravenous lidocaine, dexmedetomidine and their combination on postoperative pain and bowel function recovery after abdominal hysterectomy. Minerva Anestesiol. 2017;83(7):685–94.

17. Bajajcharya JL, Subedi A, Polkarel K, Bhattarai B. The effect of intraoperative lidocaine versus esmolol infusion on postoperative analgesia in laparoscopic cholecystectomy: a randomized clinical trial. BMC Anesthesiol. 2019;19:198.

18. Qi M, Terao Y, Toyoda T, Kuriyama T, Miura K, Fukusuki IY, et al. Differential effects of propofol and sevoflurane on QT interval during anesthetic induction. J Clin Monit Comput. 2013;27:243–8.

19. Kim EJ, Shin SW, Kim TK, Yoon JU, Byeon GJ, Kim HJ. The median effective effect-site concentration of remifentanil for minimizing the cardiovascular changes to endotracheal intubation during desflurane anesthesia in pediatric patients. Korean J Anesthesiol. 2012;63:314–20.

20. Wang K, Wu M, Xu J, Wu C, Zhang B, Wang G, et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis. Br J Anaesth. 2019;123(6):777–94.

21. Chi X, Wei X, Gao W, Guan J, Xu Y, Wang Y, et al. Dexmedetomidine ameliorates acute lung injury following orthotopic autologous liver transplantation in rats probably by inhibiting toll-like receptor 4-nuclear factor kappa B signaling. J Transl Med. 2015;13:190.

22. Liu Y, Yu Y, Zhang J, Wang C. The therapeutic effect of dexmedetomidine on protection from renal failure via inhibiting KDM5A in lipopolysaccharide-induced sepsis of mice. Life Sci. 2019;239:116868.

23. Wang SL, Duan L, Xia B, Liu Z, Wang Y, Wang GM. Dexmedetomidine preconditioning plays a neuroprotective role and suppresses TLR4/NF-κB pathways model of cerebral ischemia reperfusion. Biomed Pharmacother. 2017;93:1337–42.

24. Kang SH, Kim YS, Hong TH, Chae MS, Cho ML, Her YM, et al. Effects of dexmedetomidine on inflammatory responses in patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Scand. 2013;57(4):480–97.

25. Dong W, Chen MH, Yang YH, Zhang X, Huang M, Yang XJ, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev. 2018;6:CD006642.

26. Moeen SM, Moeen AM. Usage of intravenous lidocaine infusion with enhanced recovery pathway in patients scheduled for open radical cystectomy: a randomized trial. Pain Physician. 2019;22(2):E71–80.

27. Sridhar P, Sista SC, Ali SM, Karthikayan VS, Badhe AS, Ananthanarayanan PH. Effect of intravenous lignocaine on perioperative stress response and post-surgical ileus in elective open abdominal surgeries: a double-blind randomized controlled trial. ANZ J Surg. 2015;85(6):425–9.

28. Song X, Sun Y, Zhang X, Li T, Yang B. Effect of perioperative intravenous lidocaine infusion on postoperative recovery following laparoscopic cholecystectomy—a randomized controlled trial. Int J Surg. 2017;45:8–13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.